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Surgery on the thoracic aorta is associated with a
significant incidence of major organ dysfunction and
death.1,2 Supraceliac aortic crossclamping during
these procedures leads to transient splanchnic and
lower body ischemia. One of the possible mechanisms
involved in the pathogenesis of these complications is
endotoxemia. Studies on intestinal ischemia-reperfu-
sion have demonstrated a link between intestinal
mucosal barrier dysfunction and endotoxin (lipo-
polysaccharide [LPS]) translocation from the gut
lumen to the circulation.3,4 Similarly, lower body
ischemia-reperfusion on its own has been associated
with endotoxemia.5
Despite some evidence that endotoxemia during
aortic surgery is associated with poor outcome,6 the
clinical significance of endotoxin translocation dur-
ing major surgery and trauma has been recently
debated.7-9 The controversy over the role of endo-
toxemia after major trauma or surgery is based on
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the fact that the biologic effects of endotoxin are the
product of complex interactions between several
immune mechanisms. These mechanisms are mainly
comprised of an endotoxin recognition system (ie,
LPS binding protein, monocyte CD14, and soluble
CD14 [sCD14]),10-12 an uptake and clearance sys-
tem (ie, liver, monocytes),13 and an effector system
of several cellular and proinflammatory mediators.14
Factors affecting one or more of these mediators can
therefore indirectly modulate the host response to
endotoxemia.15-17 One such mediator that is known
to downregulate the monocyte CD14 response to
endotoxin is the immunosuppressive cytokine trans-
forming growth factor-β1 (TGF-β1).18
In this study we sought to determine the response
of the endotoxin CD14/sCD14 recognition and
effector mechanism during major aortic surgery to
assess the contribution of endotoxemia to the devel-
opment of postoperative complications in these
patients. 
PATIENTS AND METHODS
After approval by our local ethics committee,
informed consent to participate in the study was
obtained from 24 patients who were undergoing
elective Crawford types III and IV1 thoracoabdomi-
nal aortic aneurysm (TAAA) repair and 12 patients
who were undergoing elective infrarenal abdominal
aneurysm repair (AAA). All TAAA procedures were
performed with the use of the “clamp and sew”
technique without the use of bypass adjuncts. After
induction of anesthesia, radial arterial lines were
inserted; blood samples were collected at incision,
on aortic clamping (supraceliac in TAAA and
infrarenal in AAA), and immediately on reperfusion
(splanchnic in TAAA and lower limb in AAA) and at
1, 8, and 24 hours after reperfusion. Patients with
AAA were treated with heparin during the surgery;
patients with TAAA received no heparin. For this
study, major complications were defined as death,
myocardial infarction, need for ventilation for more
than 4 days, and renal failure requiring filtration.
Endotoxin measurement. For this assay, blood
samples were collected under sterile conditions into
endotoxin-free lithium heparin tubes (Quadratech,
Epsom, UK); and plasma was immediately separated
by centrifugation at 250g for 10 minutes and
aliquoted into sterile cryotubes, immediately snap-
frozen in liquid nitrogen, and later stored at –70°C
until assayed. All samples were snap-frozen within
15 minutes of collection. Plasma endotoxin levels
were assayed with the use of the Chromogenic
Limulus amebocyte lysate assay kit (Quadratech).
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Samples were tested in duplicates, and endotoxin
levels were calculated as the mean of two readings.
The test has a minimum endotoxin detection limit of
8 pg/mL. The assay was repeated if readings from
duplicates differed significantly or if exceptionally
high levels, which may indicate contamination, were
obtained. 
Peripheral blood monocyte (PBM) CD14
expression. Arterial blood samples were collected
into sterile EDTA tubes. Immediately after the col-
lection of each sample, 100 µL of whole blood were
mixed with 10 µL of PE-conjugated mouse anti-
human CD14 monoclonal antibody (Becton &
Dickinson, Oxford, UK) in a sterile cryovial. After
incubation in the dark at room temperature for 20
minutes, red blood cells were lysed by adding 1 mL
of 1% hemolysis solution (fluorescence-activated cell
sorter lysing solution; Becton & Dickinson) for 10
minutes. Samples were then centrifuged at 250g for
4 minutes, and the white cell pellets were resus-
pended in 1 mL of 1% paraformaldehyde in phos-
phate-buffered saline solution (CellFix; Becton &
Dickinson). The binding of LPS to monocyte CD14
does not affect the latter’s ability to bind its anti-
CD14 monoclonal antibodies because the binding
epitopes are different.16
Flow cytometry. Flow cytometry analysis was
performed with a flow cytometer (FACScan; Becton
& Dickinson) with a 488-nm excitation wavelength
argon laser and photomultiplier tubes at 900 to
1200 V. For each freshly stained and fixed sample,
the monocyte population was gated according to
light-forward and side-scatter characteristics; a min-
imum of 5000 events were acquired for each gated
sample. Fluorescence intensity histograms of indi-
vidual samples were analyzed with the LYSIS II soft-
ware (Becton & Dickinson). Specific fluorescence
intensity was expressed as mean channel fluores-
cence (mcf).
Soluble CD14 measurement. Arterial blood
was collected in sterile EDTA tubes and immediate-
ly centrifuged at 1000g for 10 minutes. Plasma was
aliquoted into sterile cryovials, snap-frozen, and
stored at –70°C until assayed. The assay was per-
formed with the use of an assay kit (EASIA;
Medgenix, Fleurus, Belgium). In this assay several
monoclonal antibodies directed against distinct epi-
topes of sCD14 are used, which allows for higher
sensitivity. Test samples were diluted 1:101 with
diluent buffer, and 50 µL from test and standard
samples were added to 50 µL of a biotin-conjugated
sCD14 antibody in a 96-microtiter wellplate coated
with a different anti-sCD14 antibody. After incuba-
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tion, unbound conjugate was washed and a substrate
solution was added to the wells. The optical density
of the color produced was measured with the use of
a microplate reader set at 450 and 490 nm. The
assay’s minimum detectable sCD14 concentration is
1 ng/mL. 
TGF-β1 measurement. This assay was performed
with the use of a quantitative sandwich enzyme
immunoassay kit (R&D Systems, Abingdon, UK). For
this assay, EDTA blood was collected and immediate-
ly centrifuged at 1000g for 10 minutes. The platelet-
poor plasma was separated, snap-frozen in liquid
nitrogen, and stored at –70°C until assayed. To acti-
vate latent TGF-β1 to its detectable immunoreactive
form, an activation procedure was performed whereby
100 µL of each plasma sample was added to an equal
volume of a freshly prepared acidifying solution. After
incubation for 10 minutes, the mixture was neutral-
ized by adding 100 µL of a neutralizing solution, and
the activated samples were then assayed. The mini-
mum detectable concentration for this assay is 5
pg/mL. 
Tumor necrosis factor-α measurement. Plasma
tumor necrosis factor-α (TNF-α) was measured by
the use of a quantitative sandwich enzyme immunoas-
say (R&D Systems). The minimum detectable con-
centration for this assay is 4.4 pg/mL, with a mini-
mum calibration standard of 15 pg/mL.
Data analysis. Data were analyzed with the use
of a statistical software program (SPSS, 7.5.1; SPSS
Inc, Chicago, Ill). Normally distributed data are pre-
sented as mean (SEM) and were analyzed with the
use of analysis of variance (ANOVA). Data that were
not normally distributed are presented as median
(interquartile range) and were analyzed with the use
of the Mann-Whitney U test for comparison between
groups and the Wilcoxon sign ranks test for compar-
ison within groups. Significance was assumed when
the probability value as .01 or less in all tests.
RESULTS
Table I shows demographic and risk factor analy-
ses of the patients included in this study. There was
no difference in age or other preoperative risk factors
between patients with TAAA and patients with AAA.
Intraoperatively, patients with TAAA underwent sig-
nificantly more blood transfusions than did patients
with AAA. Median ischemia time in patients with
TAAA was 70 minutes (range, 30-160 minutes) for
total aortic clamping and 44 minutes (range, 11-122
minutes) for supraceliac aortic clamping. Median
ischemia time in patients with AAA was 50 minutes
(range, 30-116 minutes). Although median ischemia
time was 20 minutes longer in patients with TAAA,
this did not reach statistical significance. Of the 24
patients with TAAA, 15 patients experienced the
development of one or more major complications.
In patients with TAAA, the mean (SEM) preop-
erative monocyte count was 0.5 (0.03) × 109/L.
This dropped to 0.3 (0.05) × 109/L immediately
after the operation (on admission to the intensive
therapy unit; P = .004, ANOVA) and remained sig-
nificantly below baseline levels for up to 48 hours
after the operation. Although none of the patients
with AAA required platelet transfusion, patients
with TAAA received a mean of two platelet pools
intraoperatively each. Mean (SEM) baseline
platelet count in patients with TAAA was 230
(21.7) × 109/L. This dropped to 145 (26) ×
109/L on admission to the intensive therapy unit
Table I. Demographic and risk factor analysis of patients with TAAA and patients with AAA
Variable TAAA AAA P value
Patients (n)
Women 9 4 —
Men 15 8 —
Median age (y; range) 69 (50-80) 70 (53-82) NS*
Crawford type III (n) 14 — —
Crawford type IV 10 — —
Median visceral ischemia (min; range) 44 (11-122) — —
Median total ischemia (min; range) 70 (30-160) 50 (30-115) NS*
Median intraoperative blood transfused (units; range) 10 (2-35) 4 (1-8) .0003*
Smokers (n) 8 4 NS†
Hypertension (n) 10 4 NS†
Ischemic heart disease (n) 4 2 NS†
Preoperative raised creatinine level (n) 6 1 NS†
NS, Not significant.
*Independent sample t-test, two-tailed P value.
†Fisher exact test.
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(P = .01, ANOVA) and remained significantly
lower than baseline levels for up to 5 days after the
operation. 
Endotoxin. Fig 1 shows the changes in plasma
endotoxin in patients with TAAA and patients with
AAA during and after surgery. Patients with TAAA
had significantly higher levels of endotoxin than
patients with AAA at clamping (P = .006, Mann-
Whitney U test), 8-hour (P = .003), and 24-hour (P
= .003) postreperfusion time points. Median peak
plasma endotoxin measured in patients with TAAA
was 133 pg/mL (range, 71.7-208.3 pg/mL) and in
patients with AAA was 41.5 pg/mL (range, 24.5-
61.7 pg/mL; P = .001). Median (interquartile range)
peak endotoxin levels in patients with TAAA with
complicated recovery were 200 pg/mL (range,
126.25-304 pg/mL), whereas in those patients who
had an uncomplicated recovery level the median peak
endotoxin levels were only 78 pg/mL (range, 49.8-
120.4 pg/mL; P = .008, Mann-Whitney U test).
PBM CD14. Fig 2 shows the changes in mono-
cyte CD14 expression in patients with TAAA and
patients with AAA. In patients with TAAA, the mean
(SEM) baseline monocyte CD14 at incision was 111
mcf (6 mcf), values dropped to 98 mcf (6.9 mcf) at
clamping (P = .1, ANOVA), to 85 mcf (7.2 mcf) at
reperfusion (P = .005), and to 63.9 mcf (5.9 mcf)
at 1 hour after reperfusion (P < .0001). At 8 hours
after reperfusion, PBM CD14 mean expression was
92.4 mcf (4.1 mcf; P = .0004), and at 24 hours
after reperfusion it recovered to 112.6 mcf (5.4
mcf; P = .8). In patients with AAA, mean blood
monocyte CD14 at incision was 105.1 mcf (5.2
mcf). During surgery mean PBM CD14 was 100.3
mcf (3.8 mcf) at aortic clamping (P = .1), 93.2 mcf
(4.8 mcf; P = .009) at reperfusion, 101.6 mcf (12
mcf) at 1 hour after reperfusion (P = .6), and 118.6
mcf (6 mcf) at 8 hours after reperfusion (P = .2). At
24 hours after reperfusion, mean CD14 levels in
patients with AAA showed a significant elevation,
Fig 1. Endotoxin levels in patients with TAAA and in patients with AAA. Data are presented
as median (interquartile range). P <.01 Mann-Whitney U test.
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reaching 143.4 mcf (7.7 mcf; P = .002). When PBM
CD14 values were compared between patients with
TAAA and patients with AAA, no significant differ-
ence was found between the two groups at the inci-
sion, aortic clamping, reperfusion, and 8 hours after
reperfusion time points. However, at 1 hour after
reperfusion, PBM CD14 expression was more signifi-
cantly downregulated in patients with TAAA (P =
.002); and at 24 hours after reperfusion, CD14
expression was more significantly upregulated in
patients with AAA (P = .002). CD14 levels showed no
significant difference between patients with TAAA
with or without major postoperative complications.
sCD14. Changes to plasma sCD14 in patients
with TAAA and in patients with AAA are shown in
Fig 3. Median (interquartile range) baseline levels
were 6.3 µg/mL (5.1-7.09 µg/mL) in patients with
TAAA and 6.3 µg/mL (5.8-7.5 µg/mL) in patients
with AAA (P > .05). Although patients with AAA
showed no significant sCD14 changes throughout
the study, patients with TAAA showed a significant
drop in sCD14 levels on supraceliac declamping, at
which time median values reached 4.74 µg/mL
(3.1-6.1 µg/mL; P = .004 from baseline), and at 1
hour after reperfusion, at which time median values
were 4.6 µg/mL (3.1-6 µg/mL; P = .0007). The
difference between sCD14 levels in patients with
TAAA and in patients with AAA was significant at
these two time points. In patients with TAAA,
sCD14 remained below baseline levels at 8 hours
after reperfusion. sCD14 levels showed no signifi-
cant difference between patients with TAAA with or
without major postoperative complications.
TNF-α. Fig 4 shows the changes in TNF-α in
patients with TAAA and in patients with AAA. At
incision, median values were 17.5 pg/mL (range,
13.5-25.25 pg/mL) in patients with TAAA and 16
pg/mL (range, 11.5-21 pg/mL) in patients with
AAA (P = .1). Although TNF-α was detectable at
incision, its levels remained within values seen in
normal control subjects.19 An increase in TNF-α
was noticed in both patients with TAAA and patients
with AAA during and after surgery; this increase was
maximal in patients with TAAA at 1 hour after
reperfusion; however, this rise was not statistically
significant (P = .03).
TGF-β1. Fig 5 shows the changes in TGF-β1
levels in patients with TAAA and in patients with
Fig 2. PBM CD14 changes in patients with TAAA and in patients with AAA. Data are pre-
sented as mean channel fluorescence. *P < .01, two-way ANOVA from incision; **P < .01, two-
way ANOVA between groups. 
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AAA. At incision median (interquartile range) con-
centration was 8 ng/mL (4.6-14.6 ng/mL) in
patients with TAAA and 7.8 ng/mL (3-15.3
ng/mL) in patients with AAA. In patients with
TAAA, TGF-β1 levels showed a significant elevation
from baseline values at the clamping (P = .01, Mann-
Whitney U test), reperfusion (P = .01), 1-hour (P =
.002), 8-hour (P = .0003), and 24-hour after reper-
fusion (P = .0005) time points. The increase in TGF-
β1 was progressive in relation to time, and by 24
hours after reperfusion, the median values were 31.7
ng/mL (21.3-40.6 ng/mL). Although an early sig-
nificant increase in TGF-β1 was observed in patients
with TAAA, patients with AAA behaved differently
and showed no significant changes in TGF-β1 levels
except at 1 hour after reperfusion (P = .007). 
Patients with TAAA had significantly higher TGF-
β1 levels than did patients with AAA at 1, 8, and 24
hours after reperfusion (P < .01, all time points). Fig
6 shows TGF-β1 levels in patients with TAAA based
on their postoperative outcome. Patients in whom
postoperative complications developed showed gen-
erally lower levels of TGF-β1 than those in whom
complications did not develop. However, this differ-
ence did not reach statistical significance except at the
clamp on time point (P = .01).
Fig 7 shows the linear regression analysis of plas-
ma peak TNF-α and peak sCD14 in patients with
TAAA. A significant positive correlation between
these two variables was observed (r = 0.83; P <
.0001). Fig 8 shows the linear regression correlation
between peak plasma endotoxin and peak PBM
CD14 in patients with TAAA. A significant negative
correlation was observed between these two vari-
ables with r = –0.73 (P < .0001). 
Bivariate analysis showed a significant negative
correlation between the highest LPS and each of the
highest TGF-β1 (r = –0.57; P = .007) and the high-
est CD14 (r = 0.6; P = .007). There was no correla-
tion between any of these parameters and visceral or
total ischemia times.
DISCUSSION 
In this study, we demonstrated that despite sig-
nificant endotoxemia, supraceliac aortic crossclamp-
ing during major aneurysm surgery is associated
Fig 3. sCD14 changes in patients with TAAA and in patients with AAA. Data are presented
as median micrograms per milliliter. *P < .01, Wilcoxon signed ranks from incision; **P < .01,
Mann-Whitney U test between groups.
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with PBM CD14 suppression, sCD14 depletion,
and no significant change in TNF-α. We have also
demonstrated that these procedures are associated
with a significant rise in TGF-β1, a pleotropic
cytokine that is known to suppress the monocyte
proinflammatory response. As expected, endotoxin
levels in patients with splanchnic ischemia-reperfu-
sion were significantly higher than in patients with
only infrarenal ischemia-reperfusion. Although
TNF-α showed no significant changes in both
groups of patients, its levels correlated significantly
with those of sCD14, supporting the role of the lat-
ter in mediating TNF-α production especially from
CD14-deficient cells.
Although endotoxin levels showed a significant
elevation in patients with TAAA before aortic cross-
clamping, this elevation was less marked than that
observed at splanchnic reperfusion. The early endo-
toxemia in patients with TAAA is most likely to be
the result of the more extensive exposure and gut
handling in these patients. 
The observation that, in the presence of serum,
only picogram concentrations of endotoxin are need-
ed to induce monocyte and vascular endothelium
stimulation19 led researchers to look for the mediators
responsible for sensitizing the host’s response to
endotoxin. Tobias et al20 described the first of such
mediators as the LPS-binding protein, an acute phase
protein capable of binding endotoxin and modulating
its effect on monocytes. The monocyte receptor
responsible for binding LPS-binding protein/LPS
complexes was identified by Wright et al16 as the sur-
face receptor CD14. With the use of specific anti-
CD14 antibodies, it was possible to demonstrate that
most of the LPS effects on monocytes and mac-
rophages are mediated through this receptor.21,22
An sCD14, which is structurally almost identical
to CD14, is found in plasma naturally. The main role
of sCD14 is to bind LPS and to facilitate its proin-
flammatory effects mainly on monocytes and on
CD14-deficient cells such as the endothelium and
epithelium.23-25 Although monocytes express CD14
and are able to respond directly to LPS, binding of
CD14 to sCD14/LPS complexes is considered to
be the major pathway for the mediation of the endo-
toxin inflammatory response.26-28
Fig 4. TNF-α levels in patients with TAAA and in patients with AAA. Data are presented as
median picograms per milliliter. 
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On in vitro exposure to endotoxin, PBMs and
macrophages upregulate their surface CD14 expres-
sion, reaching a maximum within 1 to 3 hours after
exposure.29,30 This relatively prompt CD14 upregu-
lation is not cytokine dependent31 and is due to
translocation of an intracellular pool of CD14 mole-
cules rather than an increase in its synthesis.30
Although in vitro studies of whole blood mono-
cytes showed an upregulation of CD14 on exposure
to endotoxin, studies that looked into similar
changes in vivo are few and only included patients
with multiple trauma32 and sepsis.33
In patients with multiple trauma, Heinzelmann
et al32 demonstrated that PBM CD14 is downregu-
lated. This downregulation was particularly severe in
nonsurvivors and in infected survivors; however, the
CD14 downregulation in their series was only sig-
nificant from posttrauma day 3 onwards. 
In the current study, monocyte CD14 expres-
sion showed a significant downregulation in both
patients with AAA and patients with TAAA. The
early downregulation of CD14 in these patients,
despite the associated endotoxemia, could be due
to increased shedding of this receptor or to sup-
pression of its expression. The strong negative cor-
relation found between endotoxin and CD14 is in
favor of the former mechanism, especially that oth-
ers have demonstrated an increase in sCD14 in
patients with sepsis.34,35 However, in our patients,
sCD14 showed a similar trend of depletion to that
for PBM CD14, and we therefore considered
immunosuppression after surgical trauma and
ischemia-reperfusion injury as a primary possibility.
This immunosuppression appears to be equally
potent in all patients with TAAA, regardless of
ischemia time or outcome. This is supported by the
Fig 5. TGF-β1 changes in patients with TAAA and in patients with AAA. Data are presented
as median nanograms per milliliter. *P < .01, Wilcoxon matched-pairs signed-ranks test from
incision; **P < .01, Mann-Whitney U test corrected for ties between groups.
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Fig 6. TGF-β1 changes in patients with TAAA on the basis of their postoperative outcome.
*P < .01, Mann-Whitney U test corrected for ties between groups.
Fig 7. Linear regression analysis of peak TNF-α and peak sCD14 in patients with TAAA. A
significant linear correlation was observed between these two variables (r = 0.83; P < .0001). 
JOURNAL OF VASCULAR SURGERY
Volume 31, Number 3 Hafez et al 529
lack of CD14 or sCD14 changes in patients with
TAAA with or without complications, despite the
more significant endotoxemia in the complications
group. 
TGF-β is a multifunctional polypeptide that was
initially characterized in human platelets.36 Among
its actions on monocytes are the downregulation of
CD14,18 suppression of monocyte proinflammatory
features (including procoagulant activity, tissue fac-
tor expression,37 and suppression of superoxide pro-
duction after splanchnic and myocardial ischaemia
reperfusion).38-40 The effects of TGF-β on mono-
cytes are concentration dependent with chemotactic
effects obtained at concentrations of less than 1.0
ng/mL41 and immunosuppressive effects with con-
centrations of more than 5.0 ng /mL.42
In patients with AAA, our data demonstrated no
significant rise of TGF-β1 levels, except at 1 hour after
reperfusion, and a significant upregulation of PBM
CD14 at 24 hours. In contrast, patients who under-
went the more extensive TAAA surgery and who sus-
tained thoracotomy and splanchnic ischemia-reperfu-
sion, showed a significant linear rise of TGF-β1 reach-
ing a six-fold increase from baseline levels by 24 hours
after reperfusion. The source of this TGF-β1 is most
likely to be from platelet stores. The early rise in TGF-
β1 levels in these patients could be the result of
platelet activation and trapping after thoracotomy and
lung collapse. Platelet consumption during these pro-
cedures remains a recognized problem, especially
after splanchnic reperfusion; and platelet transfusion
is routinely given at this time point.43
Although no studies on the effects of TGF-β1
release during elective major surgery are thus far
available in the literature, Meert et al44 suggested
that TGF-β1 induces immunosuppression in condi-
tions of trauma.
TGF-β1 may therefore play an important role in
modulating the immune response to endotoxemia in
major aortic surgery. The negative correlation
between monocyte CD14 and LPS and the return of
monocyte CD14 to baseline levels by 24 hours in
patients with TAAA, despite high levels of TGF-β1,
suggest, first, that the severity of CD14 suppression is
directly related to the severity of surgical stresses and
subsequently endotoxemia and, second, that the
Fig 8. Linear regression analysis of peak monocyte CD14 and peak endotoxin levels in
patients with TAAA. A significant negative correlation was found between these two variables
(r = –0.73; P < .0001).
downregulatory effect of TGF-β1 (and possibly other
yet unidentified CD14 suppressors) may be transient
and limited to the early postoperative period.
Although TGF-β1 levels were generally higher in
patients with TAAA who experienced no complica-
tions than in those patients who did, it is difficult to
infer a protective role on TGF-β1 in these patients
because the difference was only significant at one
point. This possible protective role might, however, be
better demonstrated with larger numbers of patients.
In summary, our data show a suppression of the
CD14/sCD14 mechanism despite significant endo-
toxemia in patients subjected to splanchnic ischemia-
reperfusion. The effects of endotoxemia on this mech-
anism are offset by an immunosuppressive response
associated with these procedures. Although TGF-β1
appears to play an important role in initiating this sup-
pressive response, the duration of its effect and its pos-
sible protective role require further studies.
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